Fig. 2: IRR of PASC up to 3 years after SARS-CoV-2 infection by care setting of the acute phase.
From: Three-year outcomes of post-acute sequelae of COVID-19
Heatmaps include non-hospitalized COVID-19 (n = 114,864; top rows) and hospitalized COVID-19 (n = 20,297; bottom rows) groups. IRRs were estimated in comparison to a control group without infection (n = 5,206,835). ACD, acute coronary disease; AKI, acute kidney injury; CKD, chronic kidney disease; DVT, deep vein thrombosis; ESRD, end-stage renal disease; GAD, general anxiety disorder; GERD, gastroesophageal reflux disease; IBS, irritable bowel syndrome; ICM, ischemic cardiomyopathy; ILD, interstitial lung disease; NA, not applicable; NCD, neurocognitive decline; NICM, non-ischemic cardiomyopathy; PTSD, post-traumatic stress disorder; TIA, transient ischemic attack; VTE, venous thromboembolism. If potential risk horizon (non-significant (NS) cell with a numeric IRR estimate) for an outcome was reached in a previous period, the IRRs for that outcome in all subsequent periods will not be estimated and are indicated by gray cells with NAs (not applicable) inside. yr, year.
